@article{2ac1fdb1494645c4a6628bdbcedb1e9f,
title = "The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin. Diabetes Care 2021;44:2729–2737",
author = "Ryan Bailey and Peter Calhoun and Beck, {Roy W.} and Bergenstal, {Richard M.} and Grazia Aleppo",
note = "Funding Information: ing was provided for the conduct of the analyses in this response. Study funding and study devices were provided by Dex-com, Inc. All authors received grant funding from Dexcom to their institution for the conduct of the submitted study. P.C. is a former Dexcom employee, and his current employer has received consulting payments on his behalf from vTv Therapeutics, Beta Bionics, Dexcom, and Diasome. R.W.B. reports that his institution has received funding on his behalf, including grant funding and study supplies from Tandem Diabetes Care, Beta Bionics, and Dexcom, study supplies from Medtronic, Ascencia, and Roche, consulting fees and study supplies from Eli Lilly and Novo Nordisk, and consulting fees from Insulet, Bigfoot Biomedical, vTv Therapeutics, and Diasome. G.A. reports grants from AstraZeneca, Dexcom, Eli Lilly, Insulet, and Novo Nordisk and personal fees from Dexcom and Insulet. R.M.B. reports that his employer has received funds on his behalf for research support, consulting, or serving on the scientific advisory boards for Abbott Diabetes Care, Asce-nia, Bigfoot Biomedical, Dexcom, Hygieia, Johnson & Johnson, Lilly, Medscape, Med-tronic, Novo Nordisk, Onduo, Roche, Sanofi, and UnitedHealthCare. No other potential conflicts of interest relevant to this article were reported.",
year = "2022",
month = apr,
doi = "10.2337/dci22-0006",
language = "English (US)",
volume = "45",
pages = "e85--e86",
journal = "Diabetes care",
issn = "0149-5992",
publisher = "American Diabetes Association Inc.",
number = "4",
}
